Decision Dx for uveal melanoma
Uveal melanoma is a particularly virulent type of melanoma. It has a high metastatic potential even if spead is not found at initial diagnosis and evaluation. DecisionDx is a molecular diagnostic test developed at and licensed from The University of Texas M. D. Anderson Cancer Center. The test is marketed in a specific form for a variety of cancers. The test is not FDA approved but it should be noted that Clinical Laboratory Improvement Amendments(CLIA) does not approve tests but rather certifies laboratories. (Many other tests commonly used in oncology do not have FDA clearance). This remains an experimental approach that has not been confirmed by large independent studies. There are no guidelines or consensus statements that recommend the use of this test in planning therapy or report on positive results of such a use of the test. This is especially true in using this test for the rare condition of uveal melanoma. Under a 1000 analyses have so far been performed with this test.
In general, a variety of similar tests has recently been licensed and marketed in various tumor types and at this time, none of them are generally accepted or recommended by guidelines.
For Professional version see here